ABSTR AC T Summary The first German interdisciplinary S3-guideline on the diagnosis, therapy and follow-up of patients with endometrial cancer was published in April 2018. Funded by German Cancer Aid as part of an Oncology Guidelines Program, the lead coordinators of the guideline were the German Society of Gynecology and Obstetrics (DGGG) and the Gynecological Oncology Working Group (AGO) of the German Cancer Society (DKG).
Purpose The use of evidence-based, risk-adapted therapy to treat low-risk women with endometrial cancer avoids unnecessarily radical surgery and non-useful adjuvant radiotherapy and/or chemotherapy. This can significantly reduce therapy-induced morbidity and improve the patientʼs quality of life as well as avoiding unnecessary costs. For women with endometrial cancer and a high risk of recurrence, the guideline defines the optimal surgical radicality together with the appropriate chemotherapy and/or adjuvant radiotherapy where required. The evidence-based optimal use of different therapeutic modalities should improve survival rates and the quality of life of these patients. The S3-guideline on endometrial cancer is intended as a basis for certified gynecological cancer centers. The aim is that the quality indicators established in this guideline will be incorporated in the certification processes of these centers.
Methods
The guideline was compiled in accordance with the requirements for S3-level guidelines. This includes, in the first instance, the adaptation of source guidelines selected using the DELBI instrument for appraising guidelines. Other consulted sources include reviews of evidence which were compiled from literature selected during systematic searches of literature databases using the PICO scheme. In addition, an external biostatistics institute was commissioned to carry out a systematic search and assessment of the literature for one area of the guideline. The identified materials were used by the interdisciplinary working groups to develop suggestions for Recommendations and Statements, which were then modified during structured consensus conferences and/or additionally amended online using the DELPHI method with consent being reached online. The guideline report is freely available online.
Recommendations Part 1 of this short version of the guideline presents recommendations on epidemiology, screening, diagnosis and hereditary factors, The epidemiology of endometrial cancer and the risk factors for developing endomentrial cancer are presented. The options for screening and the methods used to diagnose endometrial cancer including the pathology of the cancer are outlined. Recommendations are given for the prevention, diagnosis, and therapy of hereditary forms of endometrial cancer. 
ZUSAMMENFASSUNG

I Guideline Information
Editors Oncology Guidelines Program of the Association of Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V., AWMF), German Cancer Society (Deutsche Krebsgesellschaft e. V., DKG) and German Cancer Aid (Deutsche Krebshilfe, DKH).
Lead professional societies
The German Society for Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, DGGG) and the German Cancer Society (Deutsche Krebsgesellschaft, DKG) represented by the Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie, AGO).
This guideline was developed in cooperation with the Guideline Program of the DGGG, OEGGG and SGGG. For further information see bottom of this article.
Funding
This guideline received funding from the charity German Cancer Aid to support the German Guideline Program in Oncology (GGPO). 
Citation format
Guideline documents
The complete long version together with a summary of the conflicts of interest of all of the authors, a short version, the guideline report, and the search for external literature are available in German on the homepage of the Oncology Guidelines Program under: https://www.leitlinienprogramm-onkologie.de/leitlinien/ endometriumkarzinom/, last accessed on 13.08.2018.
Guideline authors
The working groups who contributed to this guideline consisted of members of the guideline steering committee (▶ Table 1 ), specialists nominated by participating professional societies and organizations (▶ Table 2 ), and experts invited to participate by the steering committee (▶ Table 3 ), and they are the authors of this guideline. Only mandate holders nominated by participating professional societies and organizations were eligible to vote on a chapter-by-chapter basis during the voting process (consensus ▶ process) after they had disclosed and excluded any conflicts of interest [1] . The guideline was compiled with the direct participation of two patient representatives. Physicians of the Competence Oncology Center of the National Association of Statutory Health Insurance Funds (Kompetenz Centrum Onkologie des GKV-Spitzenverbandes) and the Medical Service of German Health Funds (MDK-Gemeinschaft) were involved in an advisory capacity during the formulation of specific aspects of this S3-guideline which were relevant for social medicine.
They did not participate in the voting on individual recommendations and are not responsible for the contents of this guideline. 
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II Guideline Application
Purpose and objectives
The most important reason for compiling this interdisciplinary guideline is the high epidemiological significance of endometrial cancer and its associated burden of disease. Evidence-based riskadapted therapy to treat low-risk women with endometrial cancer can avoid unnecessarily radical surgery and non-useful adjuvant radiotherapy and/or chemotherapy. This reduces therapy-induced morbidity, improves patientsʼ quality of life and avoids unnecessary costs. For women with endometrial cancer and a high risk of recurrence, the guideline defines the optimal surgical radicality and the appropriate adjuvant chemotherapy and/or adjuvant radiotherapy. The evidence-based optimal use of different therapy modalities should improve survival rates and the quality of life of these patients.
▶ Targeted areas of patient care
The guideline covers outpatient and inpatient care.
Target patient groups
The recommendations of the guideline are aimed at all women with endometrial cancer and their relatives.
Target user groups
The recommendations of the guideline are addressed to all physicians and professionals who provide care to patients with endometrial cancer. In the first instance, this group includes gynecologists, general practitioners, radiologists, pathologists, radio-oncologists, hematologists/oncologists, psycho-oncologists, palliative care professionals and nursing staff.
Other target groups are: ▪ Scientific medical societies and professional organizations; ▪ Advocacy groups for affected women (womenʼs health organizations, patient and self-help organizations); ▪ Quality assurance institutions and projects at federal and Länder levels (AQUA, the Institute for Applied Quality Improvement and Research in Healthcare, the Association of German Tumor Centers, etc.); ▪ Health policy institutions and decision-makers at federal and Länder levels; ▪ Funding agencies.
Period of validity and update procedure
This guideline is valid from April 1, 2018 through to April 1, 2023. Regular updates are planned; if changes are urgently required, amendments will be developed which will be published in the latest version of the guideline. The aim is currently to update the guideline every two years.
III
Methodology of the Guideline
Basic principles
The method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 1.1, https://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk-offline.html, last accessed on 13.08.2018) differentiates between the lowest (S1), the intermediate (S2) and the highest (S3) class [4] . The lowest class is defined as a set of recommendations for action compiled by a nonrepresentative group of experts. In 2004, the S2 class was subdivided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest class (S3) combines both approaches. This guideline is classified as: S3.
Grading of evidence
Identified trials used in this guideline were assessed using the 2011 version of the system developed by the Oxford Centre for Evidence-based Medicine. This classifies studies according to various clinical questions (benefit of therapy, prognostic value, diagnostic validity). Further information is available online at: http:// www.cebm.net/index.aspx?o=5653, last accessed on 13.08.2018.
Grading of recommendations
The level of recommendation expresses the degree of certainty that the expected benefit of the intervention will outweigh the possible damage caused (net benefit) and that the expected positive effects will reach a level which will be relevant for the patient. Negative recommendations (must not) indicate the certainty that there will be no benefit or the result may potentially be damaging (▶ Table 4 ). The grading of recommendations incorporates the results of evaluated trials, the applicability of study results to target patient groups, the feasiblity in daily clinical practice and ethical obligations and patient preferences [2, 3] .
Recommendations
Recommendations are thematically grouped key sentences with a recommendation for action, which were developed by the guideline group and voted on in a formal consensus procedure.
Statements
Statements are expositions or explanations of specific facts, circumstances or problems with no direct recommendations for action. Statements are adopted after a formal consensus process using the same approach as that used when formulating recommendations and can be based either on study results or expert opinions.
Expert consensus (EC)
Recommendations for which no systematic systematic search of the literature was carried out are referred to as expert consensus (EC). As a rule, these recommendations cover approaches considered to be good clinical practice where no scientific studies are necessary or could be expected.
▶ Table 4 Grading of recommendations. No.
Level of recommendation
Recommendation GoR LoE Sources
3.9
Therapy with tamoxifen is a risk factor for developing endometrial cancer. The effect is dependent on the duration of administration.
ST 1 [17 -20] No.
3.10
Oral contraceptives reduce the risk for the development of endometrial carcinoma. The strength of the effect is dependent on the duration of intake. The IKNL and ACR guidelines recommend taking chest X-rays in 2 different views when making a primary diagnosis of endometrial cancer [71, 72] . It is a basic investigative procedure which primarily aims to assess the patientʼs cardiopulmonary status preoperatively and to detect and evaluate any rare pulmonary metastases. Preoperative chest radiographs show initial findings which can be used during potential follow-up examinations. Although pulmonary metastases are rare at the first manifestation of endometrial cancer, they lead to FIGO stage IV. In a retrospective multicenter study, Amkreutz et al. [73] reported that pulmonary metastases of endometrial cancer were detected in the chest radiographs of 1.3 % (7 of 541) patients. All affected patients had high-risk subtypes of endometrial cancer (serous, clear-cell or poorly differentiated endometrioid), and the incidence of pulmonary metastases was 4.1 % for these subtypes. No pulmonary metastases were detected in the chest radiographs of patients with low-risk endometrial cancer subtypes. 243 patients did not undergo thoracic imaging as a primary diagnostic procedure. The authors concluded that thoracic imaging was not required to detect metastasis in patients with low-risk subtypes of endometrial cancer. According to the study by Amkreutz et al. [73] , around 4 % of patients with high-risk subtypes had pulmonary metastasis. and the detection of metastases could be therapeutically relevant for these patients.
Abdominal ultrasound
Abdominal ultrasound is part of the basic workup, particularly to assess the internal organs including any possible preexisting urinary transport disorder. Evaluating the lesser pelvis and the retroperitoneum is difficult because of the superimposition of intestinal gases. This guideline concurs with the ACR guideline [72] which considers transabdominal ultrasound to be an unsuitable method for staging endometrial cancer. 
4.28
The report on the findings of (fractional) curettage or endometrial biopsy must provide information on the evidence for and type of endometrial hyperplasia.
If a carcinoma is detected, its histological tumor type must be defined based on the current WHO classification.
If there is evidence of tumor tissue in the cervical part of the fractional curettage specimen, every effort must be made to find evidence of or exclude endocervical stroma infiltration.
EC
4.29
The morphological workup of hysterectomy specimens must be carried out in such a way that all therapeutically and prognostically relevant parameters can be determined. The diagnostic workup must be based on the currently valid WHO classification of tumor types and the current TNM classification for staging.
EC
No.
4.30
The report on findings for hysterectomy specimens obtained from patients with endometrial cancer must include the following information:
▪ histological type according to the WHO classification ▪ for mixed tumors: information about the ratio (percentage) of the specimen compared to the overall tumor ▪ the tumor grade ▪ evidence/absence of lymph node invasion or vascular invasion (L and V status) ▪ evidence/absence of perineural invasion (Pn status) ▪ staging (pTNM) ▪ metric information about the depth of invasion compared to the myometrial thickness, in mm ▪ three-dimensional tumor size, in cm ▪ if vaginal invasion is present, metric data about the minimum distance to the vaginal resection margin ▪ R classification (UICC) EC
4.31
According to the WHO classification, mixed carcinomas of the endometrium are defined as tumors with two or more histological subtypes which are found in > 5 % of the total tumor area on microscopic examination.
The histological report on the findings must include the respective percentages of the individual histological subtypes.
EC
No.
4.23
Intraoperative histological examination may be carried out if there is a suspicion of stage pT1b and/or pT2 disease.
EC
4.24
If the surgeon is of the opinion that frozen section analysis is needed to assess the depth of myometrial infiltration and/or infiltration of the endocervical stroma of the endometrial cancer, then these two parameters must be assessed macroscopically and microscopically.
EC
4.25
Frozen section analysis must not be carried out for the purpose of grading or to determine the histological tumor type.
EC
4.26
The fallopian tubes and ovaries must be assessed macroscopically during intraoperative frozen section analysis; findings suspicious for metastasis must be examined histologically.
EC
No.
Recommendation GoR LoE Sources [81, 82] .
4.34
All resected lymph nodes in lymphadenectomy specimens obtained during surgery of a patient with endometrial cancer must be completely embedded and examined histologically. Micrometastases are defined as the histological confirmation of tumor cells in lymph nodes with diameters of ≥ 0.2 mm but not bigger than 0.2 cm.
EC
No.
4.37
The report on the findings of lymphadenectomy specimens obtained from patients with endometrial cancer must include the following information:
▪ Information about the number of affected lymph nodes compared to the number of resected lymph nodes mapped to the location where the respective lymph node was resected (pelvic, paraaortal), ▪ Information about the diameter of the largest lymph node metastasis in mm/cm, ▪ Information about the absence/evidence of any extracapsular spread of lymph node metastasis, ▪ Information about any evidence of isolated tumor cells in the lymph node as well as any evidence of lymph node invasion in perinodal fatty tissue and/or the lymph node capsule.
EC
No.
4.33
At least one representative paraffin block must be investigated during the pathological workup of an omentectomy specimen from a patient with endometrial cancer and macroscopic tumor infiltration.
Four to six paraffin blocks (several sections can be embedded in a single block) must be examined if there is no macroscopic tumor infiltration.
All other abnormal findings (e.g. intraomental lymph nodes) must be studied macroscopically and examined histologically.
EC
No.
4.38
In the setting of research studies, sentinel lymph nodes that are removed in patients with endometrial carcinoma must be fully embedded and examined in step sections. In addition, immunohistochemical examinations must be carried out ("ultrastaging") on sentinel lymph nodes that are negative on hematoxylin-eosin (HE) morphology. If the clinical criteria for another hereditary tumor syndrome with a higher risk of developing endometrial cancer have been met, the search for mutations in the probably affected genes must be carried out directly.
EC
No.
10.9
If molecular genetic testing was unable to clearly identify a pathogenic germline mutation, this does not mean that the patient has no hereditary tumor syndrome.
EC
No.
10.10
Due to the lack of any data for these special risk groups, no separate recommendations can be given regarding the benefits of dietary measures or chemoprevention for primary prevention in these groups compared to the normal population.
EC
Meets revised Bethesda criteria and/or patient develops endometrial cancer before the age of 60 years
Patient is informed in accordance with the German Genetic Diagnostics Act 
